about
Tumor suppressor and hepatocellular carcinomaNutlin-3 downregulates p53 phosphorylation on serine392 and induces apoptosis in hepatocellular carcinoma cellsNew progress of non-surgical treatments for hepatocellular carcinoma.Relationship between codon 249 mutation in exon 7 of p53 gene and diagnosis of hepatocellular carcinomaMDM2-p53 pathway in hepatocellular carcinoma.Expression of P53 and HSP70 in Chronic Hepatitis, Liver Cirrhosis, and Early and Advanced Hepatocellular Carcinoma Tissues and Their Diagnostic Value in Hepatocellular Carcinoma: An Immunohistochemical Study.Targeted p21WAF1/CIP1 activation by RNAa inhibits hepatocellular carcinoma cells.Mechanisms of doxorubicin resistance in hepatocellular carcinomaCombined modality doxorubicin-based chemotherapy and chitosan-mediated p53 gene therapy using double-walled microspheres for treatment of human hepatocellular carcinomaAdvances in experimental and translational research in the treatment of hepatocellular carcinomaSynergistic anticancer effect of exogenous wild-type p53 gene combined with 5-FU in human colon cancer resistant to 5-FU in vivo.Molecular alterations in the carcinogenesis and progression of hepatocellular carcinoma: Tumor factors and background liver factors.Potential targets for molecular imaging of apoptosis resistance in hepatocellular carcinoma.What's New in Transarterial Therapies for Hepatocellular Carcinoma?Nutlin-3 cooperates with doxorubicin to induce apoptosis of human hepatocellular carcinoma cells through p53 or p73 signaling pathways.Novel amino-modified silica nanoparticles as efficient vector for hepatocellular carcinoma gene therapy.p53 as a Dichotomous Regulator of Liver Disease: The Dose Makes the Medicine.
P2860
Q28389231-761D063F-1E47-4A45-A9E8-DBAD870E23C0Q34180073-44116CCF-22B4-4BF6-99BB-A13C3A0732ECQ34647076-309A51D3-888B-406A-8213-9F9BA9DFD0CFQ35765804-2D540901-3DF1-466D-9564-18F1BF4030E8Q35857579-EE11859B-002B-4C2D-8E45-B478959AA121Q36211990-B13EFAB3-3491-49F0-8BF2-A9C5B751DFBCQ36297935-372ACD29-C46B-403E-A095-170C1132C260Q36687760-389A7058-352A-4FC0-81F8-86B8A496886FQ36823977-5AD3C47C-46ED-4C10-8952-575026CA4327Q37122717-3F6333EE-6452-48F0-AAAE-8CEB5F8C0B8AQ37203299-5DC397FA-544E-43BD-8393-116BD0595FF4Q37407115-4EC201C7-5071-4B15-B034-75AE643CCF0CQ37886693-2BFC7B29-F4F2-4D9B-AB4F-1FEBCE1CFD81Q39572206-B89EC720-08DF-4A03-BA0D-5D79D82121EEQ39736810-E22FEAE1-9CC9-4376-9A17-F68B50B9F28AQ45855405-30636766-A1CE-4437-B544-DCA7553DCEACQ51761242-36D80807-8B89-455C-824E-8741F77C49DC
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
p53 gene in treatment of hepatic carcinoma: status quo.
@ast
p53 gene in treatment of hepatic carcinoma: status quo.
@en
type
label
p53 gene in treatment of hepatic carcinoma: status quo.
@ast
p53 gene in treatment of hepatic carcinoma: status quo.
@en
prefLabel
p53 gene in treatment of hepatic carcinoma: status quo.
@ast
p53 gene in treatment of hepatic carcinoma: status quo.
@en
P2093
P2860
P356
P1476
p53 gene in treatment of hepatic carcinoma: status quo.
@en
P2093
P2860
P304
P356
10.3748/WJG.V13.I7.985
P407
P577
2007-02-01T00:00:00Z